{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T10:51:50Z","timestamp":1790419910971,"version":"4.1.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion Clinique et Biologique"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.tracli.2017.12.001","type":"journal-article","created":{"date-parts":[[2018,1,11]],"date-time":"2018-01-11T22:36:23Z","timestamp":1515710183000},"page":"2-7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Daratumumab: Therapeutic asset, biological trap!"],"prefix":"10.1016","volume":"25","author":[{"given":"V.","family":"Deneys","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Thiry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Frelik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Debry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Doyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tracli.2017.12.001_bib0190","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1056\/NEJMra041875","article-title":"Multiple myeloma","volume":"351","author":"Kyle","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tracli.2017.12.001_bib0195","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1182\/blood-2016-03-703439","article-title":"CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma","volume":"128","author":"Nijhof","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.tracli.2017.12.001_bib0200","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13045-016-0282-1","article-title":"Novel agents in the treatment of multiple myeloma: a review about the future","volume":"9","author":"Naymagon","year":"2016","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.tracli.2017.12.001_bib0205","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/leu.2011.196","article-title":"Risk of progression and survival in multiple myeloma relapsing after therapy with IMIDs and bortezomib: a multicenter international myeloma working study group","volume":"26","author":"Kumar","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.tracli.2017.12.001_bib0210","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/MOH.0000000000000276","article-title":"New mAb therapies in multiple myeloma: interference with blood transfusion compatibility testing","volume":"23","author":"De Vooght","year":"2016","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.tracli.2017.12.001_bib0215","doi-asserted-by":"crossref","first-page":"e451","DOI":"10.1038\/bcj.2016.53","article-title":"New investigational drugs with single-agent activity in multiple myeloma","volume":"6","author":"Rajan","year":"2016","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.tracli.2017.12.001_bib0220","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1111\/trf.13267","article-title":"Transfusion management of patients receiving daratumumab therapy for advanced plasma cell myeloma","volume":"55","author":"Hannon","year":"2015","journal-title":"Transfusion"},{"key":"10.1016\/j.tracli.2017.12.001_bib0225","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","article-title":"Targeting CD38 with daratumumab monotherapy in multiple myeloma","volume":"373","author":"Lokhorst","year":"2015","journal-title":"N Eng J Med"},{"key":"10.1016\/j.tracli.2017.12.001_bib0230","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","article-title":"Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors","volume":"186","author":"de Weers","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.tracli.2017.12.001_bib0235","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1080\/19420862.2015.1007813","article-title":"Antyibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma","volume":"7","author":"Overdijk","year":"2015","journal-title":"MAbs"},{"key":"10.1016\/j.tracli.2017.12.001_bib0240","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1016\/S0140-6736(15)01226-X","article-title":"Daratumumab in multiple myeloma","volume":"387","author":"Rajkumar","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.tracli.2017.12.001_bib0245","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(15)01120-4","article-title":"Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial","volume":"387","author":"Lonial","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.tracli.2017.12.001_bib0250","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3324\/haematol.2010.030759","article-title":"Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide withe the human CD38 monoclonal antibody daratumumab","volume":"96","author":"van der Veer","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.tracli.2017.12.001_bib0255","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/blood-2016-03-705210","article-title":"Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma","volume":"128","author":"Usmani","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.tracli.2017.12.001_bib0260","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1158\/1078-0432.CCR-14-3190","article-title":"CD38-targeted immunochemotherapy in refractory multiple myeloma: a new horizon","volume":"21","author":"Laubach","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.tracli.2017.12.001_bib0265","first-page":"1095","article-title":"Potential role of daratumumab in the treatment of multiple myeloma","volume":"7","author":"Khagi","year":"2014","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.tracli.2017.12.001_bib0270","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13045-016-0283-0","article-title":"Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma","volume":"9","author":"Sanchez","year":"2016","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.tracli.2017.12.001_bib0275","doi-asserted-by":"crossref","first-page":"807","DOI":"10.4049\/jimmunol.1501351","article-title":"The therapeutic CD38 monoclonal antibody daratumumab induces programmed cell death via Fc gamma receptor-mediated crosslinking","volume":"197","author":"Overdijk","year":"2016","journal-title":"J Immunol"},{"key":"10.1016\/j.tracli.2017.12.001_bib0280","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab deplets CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.tracli.2017.12.001_bib0285","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1080\/14740338.2016.1201061","article-title":"Monoclonal antibodies for treating multiple myeloma \u2013\u00a0a new era, new safety considerations","volume":"15","author":"Oliva","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.tracli.2017.12.001_bib0290","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1182\/blood-2016-07-726729","article-title":"Phase 1\/2 study of daratumumab, menalidomide, and dexamethasone for relapsed multiple myeloma","volume":"128","author":"Plesner","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.tracli.2017.12.001_bib0295","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1515\/cclm-2015-1031","article-title":"Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference","volume":"54","author":"McCudden","year":"2016","journal-title":"Clin CHem Lab Med"},{"key":"10.1016\/j.tracli.2017.12.001_bib0300","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/j.clinbiochem.2016.07.016","article-title":"Investigation into the interference of the monoclonal antibody daratumumab on the free light chain assay","volume":"49","author":"Rosenberg","year":"2016","journal-title":"Clin Biochem"},{"key":"10.1016\/j.tracli.2017.12.001_bib0305","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1182\/blood-2015-10-646810","article-title":"Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma","volume":"127","author":"van de Donk","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.tracli.2017.12.001_bib0310","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1056\/NEJMc1515969","article-title":"Interference of new drugs with compatibility testing for blood transfusion","volume":"375","author":"Murphy","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tracli.2017.12.001_bib0315","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1111\/trf.13150","article-title":"When blood transfusion medicine becomes complicated due to interference by monoclonal antibody therapy","volume":"55","author":"Oostendorp","year":"2015","journal-title":"Transfusion"},{"key":"10.1016\/j.tracli.2017.12.001_bib0320","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1111\/trf.14144","article-title":"How do I work up pretransfusion samples containing anti-CD38?","volume":"57","author":"Anani","year":"2017","journal-title":"Transfusion"},{"key":"10.1016\/j.tracli.2017.12.001_bib0325","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1182\/blood-2016-11-749432","article-title":"Daratumumab (anti-CD38) induces loss of CD38 on red blood cells","volume":"129","author":"Sullivan","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.tracli.2017.12.001_bib0330","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, Lenalidomide, and Dexamethasone for multiple myeloma","author":"Dimopoulos","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tracli.2017.12.001_bib0335","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1182\/blood-2016-06-722496","article-title":"First report of safety and efficacy of daratumumab in 2 cases of advanced immunoglobulin light chain amyloidosis","volume":"128","author":"Sher","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.tracli.2017.12.001_bib0340","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1056\/NEJMc1605684","article-title":"Targeting CD38 in refractory extranodal killer cell T-cell lymphoma","volume":"375","author":"Hari","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tracli.2017.12.001_bib0345","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1111\/trf.13069","article-title":"Resolving the daratumumab interference with blood compatibility testing","volume":"55","author":"Chapuy","year":"2015","journal-title":"Transfusion"},{"key":"10.1016\/j.tracli.2017.12.001_bib0350","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1111\/trf.13174","article-title":"An alternative method to dithiotreitol treatment for antibody screening in patients receiving daratumumab","volume":"55","author":"Schmidt","year":"2015","journal-title":"Transfusion"},{"key":"10.1016\/j.tracli.2017.12.001_bib0355","article-title":"Daratumumab-derived anti-CD38 can be easily mistaken for clinically significant antibodies to Lutheran antigens or to Knops antigens","author":"Velliquette","year":"2015","journal-title":"Transfusion"},{"key":"10.1016\/j.tracli.2017.12.001_bib0360","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/j.1423-0410.1998.tb05433.x","article-title":"Evaluating the clinical significance of blood group alloantibodies that are causing problems in pretransfusion testing","volume":"74","author":"Garratty","year":"1998","journal-title":"Vox Sang"},{"key":"10.1016\/j.tracli.2017.12.001_bib0365","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1111\/trf.14021","article-title":"Practical approaches and costs for provisioning safe transfusions during anti-CD38 therapy","volume":"57","author":"Anani","year":"2017","journal-title":"Transfusion"},{"key":"10.1016\/j.tracli.2017.12.001_bib0370","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1111\/trf.13474","article-title":"Dealing with anti-CD38 (daratumumab) interference in blood compaitilibty testing","volume":"56","author":"De Vooght","year":"2016","journal-title":"Transfusion"}],"container-title":["Transfusion Clinique et Biologique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1246782017305414?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1246782017305414?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:36:36Z","timestamp":1761129396000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1246782017305414"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["S1246782017305414"],"URL":"https:\/\/doi.org\/10.1016\/j.tracli.2017.12.001","relation":{},"ISSN":["1246-7820"],"issn-type":[{"value":"1246-7820","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Daratumumab: Therapeutic asset, biological trap!","name":"articletitle","label":"Article Title"},{"value":"Transfusion Clinique et Biologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tracli.2017.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}